Community Health Systems, Inc. (CYH) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call highlights strong financial performance with reduced leverage and positive free cash flow. The strategic focus on AI and divestitures indicates a forward-thinking approach. Despite potential ACA headwinds, the company anticipates growth in EBITDA and revenue optimization through technology. Analysts' questions reveal confidence in management's strategies. Overall, the positive outlook and strategic initiatives suggest a likely positive stock price movement in the short term.
Key Financial Performance
Same-store net revenue Increased 2.1% year-over-year, driven by a 2.4% increase in net revenue per adjusted admission. This reflects higher acuity and a slight improvement in payer mix.
Adjusted EBITDA $395 million for the fourth quarter with a margin of 12.7%. Adjusted EBITDA was up slightly versus the fourth quarter of 2024 when accounting for divestitures and out-of-period items.
Same-store inpatient admissions and adjusted admissions Each down 0.3% year-over-year. When excluding Pennsylvania operations divested in early 2026, admissions and adjusted admissions were flat year-over-year.
Same-store surgeries Declined 1.9% year-over-year. When excluding Pennsylvania operations divested in early 2026, surgeries were down 0.4%.
ED visits Down 3.6% year-over-year. When excluding Pennsylvania operations divested in early 2026, ED visits were flat year-over-year.
Labor costs Growth in average hourly wage rate was within the expected range for the quarter and full year. Contract labor spend was essentially flat both sequentially and year-over-year.
Medical specialist fees $169 million in the fourth quarter, up 4.6% year-over-year on a same-store basis. This was driven by radiology and anesthesia costs.
Cash flows from operations $266 million for the fourth quarter, bringing the full year total to $543 million versus $480 million in 2024. Adjusted cash flows from operations (excluding taxes on divestiture gains) were $712 million for 2025.
Adjusted free cash flows $150 million for 2025.
Leverage Reduced from 7.4x at year-end 2024 to 6.6x at year-end 2025, reflecting debt reduction efforts.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ER Expansion: ER visits increased by over 13% in Knoxville hospitals over the past 2 years due to a major investment in ER expansion at Tennova North Knoxville in 2024. Another investment at Tennova Turkey Creek in Knoxville, to be completed in summer 2025, will add more ER beds.
Women's Services Expansion: A $10 million investment in women's services at Grandview Medical Center in Birmingham, Alabama, led to a 20% increase in births, with over 4,000 babies born in 2025.
Cardiac Care Program: Heart surgeries increased by 16% in Longview, Texas, in 2025 due to the development of a high-quality cardiac care program.
Inbound Transfers: Carlsbad, New Mexico, saw a nearly 35% increase in inbound transfers, with over 450 patients coming from communities up to 100 miles away for higher acuity care.
Cost Controls: Labor costs were well managed, with contract labor spend flat year-over-year and live expense declining 110 basis points year-over-year to 14.4% of net revenue in Q4 2025.
Debt Reduction: Leverage reduced from 7.4x at year-end 2024 to 6.6x at year-end 2025, with further reductions expected in 2026 due to proceeds from divestitures.
Divestitures: Several divestitures in 2025 allowed reinvestment into core portfolio and debt reduction. Notable divestitures include Tennova Healthcare, Clarksville, and three Pennsylvania hospitals.
Vision and Priorities: CHS adopted five priorities: improving quality, physician experience, patient experience, employee satisfaction, and growing cash flows to invest in growth opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic disruptions impacting patient behavior: The company experienced economic disruptions in 2025 that affected patient behavior, creating challenges in maintaining consistent patient volumes and revenue.
Regulatory uncertainty in reimbursement and insurance coverage: Regulatory changes created uncertainty in reimbursement rates and insurance coverage, posing risks to financial stability and operational planning.
Upward pressure on medical specialist fees: Medical specialist fees, particularly in radiology and anesthesia, are expected to grow by 5% to 8% in 2026, adding cost pressures to the company.
Decline in same-store surgeries and ED visits: Same-store surgeries declined by 1.9% and ED visits were down 3.6% in 2025, indicating challenges in maintaining patient volumes.
Impact of divestitures on revenue and EBITDA: Divestitures completed in 2025 and planned for 2026 are expected to reduce net revenue and EBITDA, impacting financial performance.
Reduction in HICS enrollment: A reduction in HICS enrollment is estimated to have a $20 million to $30 million EBITDA impact in 2026, affecting financial outcomes.
Extra pay period in 2026: An additional pay period in 2026 will create a $140 million headwind to cash flows from operations, adding financial strain.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Net Revenue: Anticipated to be between $11.6 billion to $12.0 billion for 2026, reflecting the impact of completed and announced divestitures as well as the exclusion of one-time or out-of-period items that benefited 2025 results.
Adjusted EBITDA: Expected to range from $1.34 billion to $1.49 billion in 2026, with a 4% growth in core operations net of a $20 million to $30 million EBITDA impact from the reduction of HICS enrollment.
Cash Flows from Operations: Projected to be between $600 million to $700 million in 2026, with a $140 million headwind due to an extra pay period in the year.
Capital Expenditures: Estimated to be between $350 million to $400 million for 2026.
Debt Reduction: Net debt expected to decrease to approximately $9.2 billion following the completion of the Huntsville divestiture in 2026, down from $10.1 billion at year-end 2025.
Divestitures Impact: Divestitures completed in 2025 and early 2026 are expected to reduce EBITDA by $110 million to $130 million in 2026.
Medical Specialist Fees: Anticipated to grow by 5% to 8% in 2026, driven by radiology and anesthesia.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's perspective on further divestitures and the impact on future performance?
A:The company is nearing the end of its programmatic divestitures, with some inbound interest still present. There are a couple of transactions in early discussions, but their completion is uncertain. The company is comfortable with its current portfolio and plans to be opportunistic about divestitures, focusing on transactions that could materially deleverage or adapt to changes in the economic environment.
Q:What assumptions are embedded in the HICS adjustment in the guidance?
A:Health care exchanges represent less than 5% of total adjusted admissions and net revenue. The guidance accounts for potential impacts from reductions in enrollment due to administrative reforms, expiration of enhanced premium tax credits, and other factors. A 20% reduction in fixed volumes could result in a $100 million to $120 million reduction in net revenue and a $20 million to $30 million reduction in EBITDA.
Q:How has the portfolio's performance varied across different markets and hospital types?
A:The portfolio has a wide range of performance. Smaller, rural hospitals often serve as access or transfer points for higher acuity services within a network. The company has focused on divesting standalone hospitals and building networks of care around suburban or midsized metropolitan areas.
Q:Does the company's positive free cash flow change its view on capital spending, and what are its plans regarding AI investments?
A:The company has turned free cash flow positive due to initiatives like the divestiture program. Capital spending levels remain consistent, with more spending per hospital due to a smaller footprint. AI investments include administrative cost-saving tools, virtual patient sitters, documentation accuracy tools, and clinical tools like maternal fetal early warning systems. The company is also leveraging AI in its ERP system for further efficiencies.
Q:What is the revenue bridge for 2025, including divestitures and one-time items?
A:The partial year impact of divestitures in 2025 is a $210 million to $230 million reduction in net revenue. Announced and completed divestitures for early 2026 will reduce net revenue by about $1 billion. One-time items like the Tennessee SDP and opioid settlement add $60 million to net revenue. The jump-off point for 2025 net revenue is approximately $11.2 billion.
Q:What is the company's outlook on consumer confidence and its impact on 2026 performance?
A:Consumer confidence dipped in December 2025, which may create headwinds in early 2026. The company expects improvement throughout the year, with stronger EBITDA production in the back half of 2026.
Q:What is the expected same-facility EBITDA growth for 2026, and what factors contribute to it?
A:The expected same-facility EBITDA growth is approximately 6%. Contributing factors include a 2.5% to 3.5% rate increase, favorable Medicare rates (4% increase for 2026), payer mix improvements, and higher acuity services driven by capital growth investments.
Q:How does the company address potential fixed cost leverage leakage from divestitures?
A:The company manages overhead costs efficiently, with centralized services that are volume-related and scalable. It has added significant numbers of beds and facilities like freestanding EDs and surgery centers to its core portfolio. Despite a 35% reduction in facilities since 2019, net revenues and EBITDA remain relatively close to previous levels.
Q:What are the details of the ERP implementation and its impact on efficiencies and savings?
A:The ERP implementation was completed on time and has saved approximately $50 million in 2025. Savings come from reducing duplicative systems, better decision support, and leveraging scale. The system provides standardized data and insights, particularly in supply chain management. AI components in the ERP are expected to drive further efficiencies in 2026 and beyond.
Q:What are the company's efforts in revenue optimization through technology?
A:The company uses AI in appeals processes, autonomous coding, and prior authorization. Vendors are building AI technology into revenue cycle software, which will help with charge capture and other efficiencies.
Q:What is the impact of ACA headwinds on EBITDA, and what are the offsetting factors?
A:The ACA headwind is estimated at $20 million to $30 million in EBITDA, despite a potential $100 million to $120 million revenue impact. Offsetting factors include low collection rates for co-pays and deductibles from exchange patients, and some patients transitioning to commercial coverage or Medicaid.
Q:What is the company's same-store volume growth assumption for 2026, and which payer categories are expected to drive improvement?
A:The same-store volume growth assumption is low single digits. Improvement is expected in commercial and Medicare payer categories, driven by capital and service line investments.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the percentage of exchange enrollment loss that might transition to other coverage sources. They stated it was too early to predict accurately and did not provide specific assumptions or data to clarify the impact.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alabama investment
CEO Community
CEO employee
CEO people
CFO CEO
CHS Today
CHS point
CHS today
Carlsbad New
Creek Knoxville
Directors support
ER bed
ER expansion
Executive VP
Full Conference
Grandview year
Knoxville hospital
Knoxville summer
Longview
Tennova
capital structure
care experience
community
confidence
core portfolio
disruption
employee physician
example
heart
opportunity market
priority
role
standpoint
vision
woman service
CYH Transcript
Community Health Systems, Inc. (CYH) Q4 2025 Earnings Call Transcript
Positive2-19
The company's earnings call highlights strong financial performance with reduced leverage and positive free cash flow. The strategic focus on AI and divestitures indicates a forward-thinking approach. Despite potential ACA headwinds, the company anticipates growth in EBITDA and revenue optimization through technology. Analysts' questions reveal confidence in management's strategies. Overall, the positive outlook and strategic initiatives suggest a likely positive stock price movement in the short term.
Community Health Systems, Inc. (CYH) Presents at UBS Global Healthcare Conference 2025 Transcript
Neutral11-11
Community Health Systems, Inc. (CYH) Q3 2025 Earnings Call Transcript
Unknown10-24
The earnings call reveals mixed signals. Financial performance shows slight improvements in margins and leverage, but operational challenges persist with declining surgeries and ER visits. The cautious guidance and lack of specific divestiture plans contribute to uncertainty. However, positive factors like payer mix improvements and strategic capital deployment balance the sentiment. Overall, the sentiment remains neutral due to the absence of decisive positive or negative catalysts.
Community Health Systems, Inc. (CYH) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-14
CYH Slides
CYH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
